Código 300630 (Harmonized System 2012 by 6 digits)
2024: US$54.1M, Total Trade Exchange
2024: US$1.31M, International Sales
2024: US$52.8M, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient was US$54.1M.
In 2024, the states with the most international sales in Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were Ciudad de México (US$219k).
The states with the most international purchases in 2024 were Ciudad de México (US$50.9M) and Estado de México (US$1.57M).
In 2024, the main commercial destinations of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were Norway (US$122k), Panama (US$94.4k), Peru (US$2.19k), and Ireland (US$299).
The main commercial origins of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient in 2024 were Germany (US$20.5M), United States (US$11.9M), Italy (US$8.5M), France (US$3.99M), and Ireland (US$3.87M).
In the global context, the main exporting countries of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient in 2022 were Germany (US$952M), Ireland (US$542M), and China (US$515M). In the same year, the main importing countries of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were United States (US$933M), China (US$297M), and France (US$199M).
US$54.1M, Total Trade Exchange (2024)
In 2024, the total trade exchange of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient in Mexico (including international purchases and sales) was US$54.1M.
The visualizations show the net balance of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
March, 2025: US$5.52M, International Purchases
In March 2025, international sales of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were US$0, while international purchases reached US$5.52M. The above results in a trade balance of -US$5.52M.
Ciudad de México: US$219k, State with the Most International Sales (2024)
Norway: US$122k, Main commercial destination (2024)
In 2024, the states with the highest international sales in Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were Ciudad de México (US$219k).
In 2024, the countries with the most international purchases from Mexico were Norway (US$122k), Panama (US$94.4k), Peru (US$2.19k), and Ireland (US$299).
Ciudad de México: US$50.9M, State with the Most International Purchases (2024)
Germany: US$20.5M, Main Commercial Origin (2024)
In 2024, the states with the highest international in Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were Ciudad de México (US$50.9M) and Estado de México (US$1.57M).
The countries with the most international sales to Mexico in 2024 were Germany (US$20.5M), United States (US$11.9M), Italy (US$8.5M), France (US$3.99M), and Ireland (US$3.87M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were Germany (US$952M), Ireland (US$542M), and China (US$515M). In the same year, the main importing countries for Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were United States (US$933M), China (US$297M), and France (US$199M).